TerminatedPhase 2NCT02446860

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

Studying Hereditary clear cell renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Royal Marsden NHS Foundation Trust
Principal Investigator
James Larkin
Royal Marsden NHS Foundation Trust
Intervention
nivolumab(drug)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
20152018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02446860 on ClinicalTrials.gov

Other trials for Hereditary clear cell renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary clear cell renal cell carcinoma

← Back to all trials